Multifunctional polymer-integrated titanium oxide nanoscaffold stimulates bone formation co-culturing bone marrow mesenchymal stem cells to treat osteonecrosis

The management of refractory bone abnormalities is a significant preclinical trial, particularly in Osteonecrosis (ON), which is considered by inadequate angiogenesis and osteogenesis. A scaffold responsive to micromilieu changes, comprising poly-L-lactide (PLA) and titanium (TiO 2 ) nanoparticles (NPs), is engineered to improve bone formation by reactive oxygen species (ROS) scavenging and regulating the in situ immunological micromilieu. An enzyme catalase reaction involving TiO 2 and hydrogen peroxide (H 2 O 2 ) produced in the acidic, ROS-rich milieu of a bone defect induces the controlled release of oxygen and Ti 2+ . This process markedly enhances the inflammatory response by facilitating M2-type macrophage polarization and reprogramming the osteo-immune micromilieu to support angiogenesis and osteogenesis. Additionally, a study revealed that PLA/TiO 2 nanoscaffolds (PTi) enhance the osteogenic potential of human bone marrow mesenchymal stem cells (BMMSCs). The PTi demonstrates exceptional immunomodulatory capabilities and outstanding angiogenic and osteogenic properties, making it a viable candidate for bone graft substitutes in the treatment of clinically refractory bone abnormalities.